← Leaderboards
Richard J. Barohn
University Of Texas Sw Med Ctr/Dallas
$34,290,842
Attributed
$41,136,088
Total exposure
37
Grants
35
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $7.9M · FY2007–20$10M$7.5M$5M$2.5M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$39,451,070 · 34
FDA$4,876,287 · 4
By mechanism
UL1$27,517,659 · 8
R01$4,876,287 · 4
U01$4,524,279 · 1
KL2$3,106,821 · 2
U10$2,072,857 · 1
M01$1,463,195 · 17
Top collaborators
- Jonathan M. Goldstein5 shared
- David A. Hafler5 shared
- Richard Nowak5 shared
- Jonathan Katz4 shared
- Dan Moore4 shared
- Russell H Swerdlow4 shared
- Yunxia Wang4 shared
- Lauren S. Aaronson3 shared
Others in their field
Top investigators on “Funding”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,479,940,681
- Leonard Freedman · Leidos Biomedical Research, Inc.$968,195,877
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Jeffrey P Krischer · University Of South Florida$358,470,093
Research focus
FundingResearch PersonnelClinical ResearchResourcesGrantInstitutionUnited States National Institutes Of HealthBaseClinical TrialsInstitutesTranslational ResearchSourceResponseResearch InfrastructureProgramsUniversitiesKansasMedicalInnovationPharmaceutical PreparationsCitiesFacultyClinical SciencesTraining
Grant awards (73)
Phase 2B Trial of Memantine for the Treatment of Amyotrophic Lateral Sclerosis$333,492
R01 · FY2020 · FD · contact PI
Phase 2B Trial of Memantine for the Treatment of Amyotrophic Lateral Sclerosis$214,856
R01 · FY2019 · FD · contact PI
Phase 2B Trial of Memantine for the Treatment of Amyotrophic Lateral Sclerosis$105,821
R01 · FY2019 · FD · contact PI
Frontiers: University of Kansas Clinical and Translational Science Institute$4,023,804
UL1 · FY2018 · TR · contact PI
Frontiers: University of Kansas Clinical and Translational Science Institute$4,063,704
UL1 · FY2017 · TR · contact PI
Heartland Unit for Neuroscience Trials$300,000
U10 · FY2017 · NS · contact PI
A Phase II Trial of Rituximab In Myasthenia Gravis$964,955
U01 · FY2016 · NS
Phase 2 Study of Rasagiline for Treatment of Amyotrophic Lateral Sclerosis$384,448
R01 · FY2016 · FD · contact PI
Heartland Unit for Neuroscience Trials$300,000
U10 · FY2016 · NS · contact PI
A Phase II Trial of Rituximab In Myasthenia Gravis$183,022
U01 · FY2016 · NS
Models of Neuromuscular Disease Across the Lifespan$16,000
R13 · FY2016 · NS · contact PI
Heartland Institute for Clinical and Translational Research$3,180,892
UL1 · FY2015 · TR · contact PI
A Phase II Trial of Rituximab In Myasthenia Gravis$1,011,907
U01 · FY2015 · NS
Heartland Institute for Clinical and Translational Research$632,191
KL2 · FY2015 · TR · contact PI
Phase 2 Study of Rasagiline for Treatment of Amyotrophic Lateral Sclerosis$391,431
R01 · FY2015 · FD · contact PI
Heartland Unit for Neuroscience Trials$287,000
U10 · FY2015 · NS · contact PI
Heartland Institute for Clinical and Translational Research$141,716
TL1 · FY2015 · TR · contact PI
Heartland Institute for Clinical and Translational Research$3,225,880
UL1 · FY2014 · TR · contact PI
A Phase II Trial of Rituximab In Myasthenia Gravis$1,059,022
U01 · FY2014 · NS
Heartland Institute for Clinical and Translational Research$591,909
KL2 · FY2014 · TR · contact PI
Phase 2 Study of Rasagiline for Treatment of Amyotrophic Lateral Sclerosis$390,367
R01 · FY2014 · FD · contact PI
Heartland Unit for Neuroscience Trials$300,000
U10 · FY2014 · NS · contact PI
Heartland Institute for Clinical and Translational Research$139,798
TL1 · FY2014 · TR · contact PI
Heartland Institute for Clinical and Translational Research$3,108,438
UL1 · FY2013 · TR · contact PI
A Phase II Trial of Rituximab In Myasthenia Gravis$1,305,373
U01 · FY2013 · NS
Heartland Institute for Clinical and Translational Research$600,660
KL2 · FY2013 · TR · contact PI
Heartland Unit for Neuroscience Trials$285,857
U10 · FY2013 · NS · contact PI
Phase 2B Trial of Memantine for the Treatment of Amyotrophic Lateral Sclerosis$184,964
R01 · FY2013 · FD · contact PI
Phase 2B Trial of Memantine for the Treatment of Amyotrophic Lateral Sclerosis$145,000
R01 · FY2013 · FD · contact PI
Heartland Institute for Clinical and Translational Research$133,537
TL1 · FY2013 · TR · contact PI
Heartland Institute for Clinical and Translational Research$3,197,840
UL1 · FY2012 · TR · contact PI
Heartland Institute for Clinical and Translational Research$629,476
KL2 · FY2012 · TR · contact PI
Phase II Trial of methotrexate in myasthenia gravis FDA IND#:101,306 01/06/2008$396,508
R01 · FY2012 · FD · contact PI
Phase 2 Study of Rasagiline for Treatment of Amyotrophic Lateral Sclerosis$396,505
R01 · FY2012 · FD · contact PI
Drug Repurposing and Rediscovery for Gastrointestinal Stromal Tumors$334,563
UL1 · FY2012 · TR · contact PI
Heartland Unit for Neuroscience Trials$300,000
U10 · FY2012 · NS · contact PI
Heartland Institute for Clinical and Translational Research$133,537
TL1 · FY2012 · TR · contact PI
Heartland Institute for Clinical and Translational Research$3,191,269
UL1 · FY2011 · RR · contact PI
CTSA INFRASTRUCTURE FOR CLINICAL TRIALS$1,855,531
UL1 · FY2011 · RR · contact PI
HEARTLAND INSTITUTE FOR CLINICAL AND TRANSLATIONAL RESEARCH$834,996
UL1 · FY2011 · RR · contact PI
Heartland Institute for Clinical and Translational Research$652,585
KL2 · FY2011 · RR · contact PI
Phase II Trial of methotrexate in myasthenia gravis FDA IND#:101,306 01/06/2008$389,739
R01 · FY2011 · FD · contact PI
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCH$309,266
UL1 · FY2011 · RR · contact PI
Heartland Unit for Neuroscience Trials$300,000
U10 · FY2011 · NS · contact PI
Heartland Institute for Clinical and Translational Research$131,671
TL1 · FY2011 · RR · contact PI
CTSA INFRASTRUCTURE FOR AIDS RESEARCH$95,738
UL1 · FY2011 · RR · contact PI
CTSA INFRASTRUCTURE FOR AIDS RESEARCH$95,738
UL1 · FY2011 · RR · contact PI
Phase II Trial of methotrexate in myasthenia gravis FDA IND#:101,306 01/06/2008$397,306
R01 · FY2010 · FD · contact PI
Phase II Therapeutic Trial of Mexiletine$100,485
R01 · FY2010 · FD · contact PI
Phase II Trial of methotrexate in myasthenia gravis FDA IND#:101,306 01/06/2008$397,403
R01 · FY2009 · FD · contact PI
Phase II Therapeutic Trial of Mexiletine$298,832
R01 · FY2009 · FD · contact PI
CLINICAL TRIAL: GENTAMICIN IN DUCHENNE MD$101,462
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: RITUXIMAB IN DM AND PM$72,846
M01 · FY2009 · RR · contact PI
ANDERSON-TAWIL SYNDROME$23,414
M01 · FY2009 · RR · contact PI
CINCH$19,512
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: ETANERCEPT IN DERMATOMYOSITIS$18,212
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: MEXILETINE IN NDM$13,007
M01 · FY2009 · RR · contact PI
EPISODIC ATAXIA STUDY$2,610
M01 · FY2009 · RR · contact PI
Phase II Therapeutic Trial of Mexiletine$349,130
R01 · FY2008 · FD · contact PI
CLINICAL TRIAL: RITUXIMAB IN DM AND PM$136,384
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: GENTAMICIN IN DUCHENNE MD$24,932
M01 · FY2008 · RR · contact PI
CINCH$23,462
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: COQ10 IN ALS$11,733
M01 · FY2008 · RR · contact PI
EPISODIC ATAXIA STUDY$2,934
M01 · FY2008 · RR · contact PI
RITUXIMAB TREATMENT OF REFRACT ADULT & JUVENILE DERMATOMYOSITIS(DM) & ADULT (PM)$199,487
M01 · FY2007 · RR · contact PI
CLINICAL INVESTIGATION OF NEUROLOGICAL CHANNELOPATHIES(CINCH)$56,930
M01 · FY2007 · RR · contact PI
CLINICAL TRIAL OF HIGH DOSE COQ10 IN ALS$47,442
M01 · FY2007 · RR · contact PI
11th International Myasthenia Gravis Meeting$35,000
R13 · FY2007 · NS · contact PI
International Conference on the Non-Dystrophic Myotonias$35,000
R13 · FY2007 · NS · contact PI
A DOUBLE-BLIND, PLACEBO-CONTROL TRIAL OF ETANERCEPT IN DERMATOMYOSITIS$31,242
M01 · FY2007 · RR · contact PI
IVIG IN GENERALIZED MYASTHENIA GRAVIS$321,374
M01 · FY2002 · RR
IVIG IN GENERALIZED MYASTHENIA GRAVIS$321,374
M01 · FY2001 · RR
IVIG IN GENERALIZED MYASTHENIA GRAVIS$34,838
M01 · FY2000 · RR